Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.45 |
| ▸ | AHCY | P23526 | 1/20 | 0.42 |
| ▸ | ADA | P00813 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486632 | 0.86 | DNMT3B (0.47) | DNMT3B | |
| SCHEMBL4621109 | 0.85 | DNMT3B (0.52) | DNMT3BPRMT5WDR77AHCYADA | |
| SCHEMBL17515059 | 0.84 | DNMT3B (0.47) | DNMT3BPRMT5WDR77AHCYADA | |
| SCHEMBL11568109 | 0.84 | DNMT3B (0.47) | DNMT3B | |
| SCHEMBL18486651 | 0.83 | DNMT3B (0.44) | DNMT3B | |
| SCHEMBL7170446 | 0.82 | ADORA3 (0.56) | DNMT3B | |
| SCHEMBL18486626 | 0.82 | DNMT3B (0.44) | DNMT3B | |
| Nebularine SCHEMBL10666450 | 0.80 | ADA (0.65) | DNMT3BADAKDM4EPKM | |
| Nebularine SCHEMBL9644429 | 0.80 | ADA (0.65) | DNMT3BADAKDM4EPKM | |
| Nebularine SCHEMBL742475 | 0.80 | ADA (0.65) | DNMT3BADAKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| EP-2204154-A1 | Association of monosaccharides and adenosine and its cosmetic use | L'OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | claimed |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-11-24 | — | — | US | disclosed |
| EP-4025582-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-07-13 | — | — | EP | disclosed |
| CN-114728999-A | Oligonucleotides containing nucleotide analogs | 赛诺菲 | 2022-07-08 | — | — | CN | disclosed |
| EP-3762395-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | Sanofi (FR) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019170731-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2019-09-12 | — | — | WO | disclosed |
| EP-1019426-A1 | NOVEL A 1? ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | THE UNIVERSITY OF FLORIDA (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1997024363-A1 | NOVEL A1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF FLORIDA (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5055569-A | Gastrointestinal disorders | G. D. SEARLE & CO. (US) | 1991-10-08 | — | — | US | disclosed |
| EP-0423777-A2 | Method of treating gastrointestinal motility disorders | G.D. Searle & Co. (US) | 1991-04-24 | — | — | EP | disclosed |
| EP-0423776-A2 | N-(6)-substituted adenosine compounds | G.D. Searle & Co. (US) | 1991-04-24 | — | — | EP | disclosed |
| EP-0179631-B1 | N6-ACENAPHTHYL ADENOSINES AND ANALOGS THEREOF | WARNER-LAMBERT COMPANY (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4673670-A | TREATING ANGINA | WARNER-LAMBERT COMPANY (US) | 1987-06-16 | — | — | US | disclosed |
| US-4614732-A | HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0179631-A2 | N6-acenaphthyl adenosines and analogs thereof | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | RNMT, RRM2B, RRM2 | DNMT3B 493/4885PRMT5 2920/4885WDR77 368/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | DNMT3B 206/4885PRMT5 3623/4885WDR77 663/4885 |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | DNMT3B 1675/4885PRMT5 715/4885WDR77 910/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | DNMT3B 406/4885PRMT5 3537/4885WDR77 572/4885 |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | DCLRE1B, UPF1, IGF2BP1 | DNMT3B 861/4885PRMT5 3223/4885WDR77 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.